Ns are based on total participants successfully genotyped. CONCLUSION: Conclusion: Evidence suggests abnormal levels of the hormone GDF15 are associated with HG. Validation of the GDF15 receptor gene GFRAL as a genetic risk factor for HG provides further support that the GDF15-GFRAL pathway is involved in disease etiology. Additionally, the progesterone receptor PGR, like GDF15, plays a role in the developing placenta and gastrointestinal mobility. Our findings validate PGR as a genetic risk factor for HG. GDF15 inhibitors have proven successful in restoring body weight and appetite in animal models of cachexia, making this a promising strategy for treating NVP and HG. Therapeutics targeting GFRAL and PGR should also be investigated. 
906 FXI deficiency found on expanded carrier screening: A quandary in routine obstetric management 
OBJECTIVE:
The routine use of prenatal carrier screening has resulted in increased identification of carriers for Factor XI (FXI) deficiency, a rare inherited coagulation disorder with variable bleeding phenotypes. The objective of this study is to describe the management and pregnancy outcomes of patients with no bleeding history who screened positive for FXI deficiency. STUDY DESIGN: This is a prospective analysis of data obtained from asymptomatic patients who tested positive for FXI deficiency through expanded carrier screening between 01/2014 and 05/2018. We describe characteristics of this population and clinical history that may be associated with an increased risk of bleeding complications, management of these patients, and pregnancy outcomes. RESULTS: 46 patients, of whom 1 was homozygous (FXI level <11 %) and 45 were heterozygous for FXI deficiency, were included in the analysis. Patient demographics are presented in Table 1 . 76% of the heterozygous patients reported a prior hemostatic challenge (major surgery or wisdom tooth extraction) with only 2 having had excessive bleeding. Median FXI level for the 43 heterozygous patients with no history of increased bleeding was 48% (IQR: 41:58). None of these patients had levels below 15%; 16% were between 26-35% and 28% between 36 and 50%. The rest of this cohort had FXI levels > 50%. 6 patients received FFP (1-3 Units) prior to regional anesthesia or delivery based on hematologist recommendation and none received TXA prophylaxis. Median FXI levels for the 6 patients that received FFP prophylaxis was 34% (IQR:30,42), compared to 48% (IQR:41,58) in the group that did not. None of the remaining patients required FFP or TXA at the time of delivery for excessive bleeding and 26 of them (70%) received regional anesthesia uneventfully. Only 1 patient required FFP after c-section due to a subcutaneous hematoma (FXI level 32%). Additional outcomes are shown in Table 2 . CONCLUSION: Patients found incidentally to have FXI deficiency during carrier screening have a wide range of FXI levels and guidance on the obstetric management of these patients is non-existent. The majority of patients have an uncomplicated course of labor and delivery and do not require prophylactic treatment with FFP or TXA. More studies are needed to further establish the optimal approach to these patients. Figure 1 ). There was no significant difference in score between those who felt good vs. moderate vs. fair about the information provided to them during counseling (P¼0.84). CONCLUSION: There are significant knowledge gaps among patients regarding cfDNA screening, regardless of who provides the counseling. More efforts need to be made for counseling to be at the educational level of the patient.
Preterm birth etiologies in Marfan syndrome
and Loeys-Dietz syndrome OBJECTIVE: Women with Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS), connective tissue disorders with genetic-predisposition for aortic dissection, have been reported to have a higher rates of preterm birth, but it is unclear whether this is due to iatrogenic or spontaneous causes. The objective of this study was to evaluate the etiology of preterm birth in a cohort of women with MFS and LDS. STUDY DESIGN: We conducted a retrospective observational cohort study of women with a clinical and genetic diagnosis of MFS or LDS who had previously been pregnant. Women were recruited through the National Marfan Foundation website and through the connective tissue clinic at Johns Hopkins Hospital. A woman's first singleton pregnancy was included. Women with incomplete information and those who delivered before 1990 were excluded. The primary outcome was the cause of preterm birth. Women who were diagnosed with MFS/LDS after their pregnancy were also compared to women who received the diagnosis prior to pregnancy in an attempt to identify how medical management changes due to disease diagnosis. RESULTS: A total of 128 pregnancies in women with MFS/LDS were included in the analysis (MFS¼104, LDS¼24). The total preterm rate in this cohort was 48% (N¼61). There was a higher rate of spontaneous preterm birth as compared to iatrogenic preterm birth (87% vs. 13%). Even among women who were not diagnosed with MFS/LDS until after their pregnancy (n¼ 35), there was a high rate of preterm birth, 45% (N¼16), and the majority was spontaneous (94%). As compared to women diagnosed after their pregnancy, those diagnosed prior to their pregnancy were more likely to deliver at an earlier gestational age (36.8 vs. 38.4 weeks, p<0.001), receive general anesthesia (14% vs 3%, p<0.001) and have a cesarean delivery (54% vs 20%, p<0.001). The primary reason for 80% of the cesarean deliveries in the group diagnosed prior to pregnancy was listed as connective tissue disorder. CONCLUSION: In agreement with previous literature, this study highlights that women with MFS and LDS are at higher risk for preterm birth. This risk appears to be driven by spontaneous rather than iatrogenic preterm birth. 
OBJECTIVE:
The fetal fraction of circulating cell-free DNA (cfDNA) is placental in origin, and is a critical variable in noninvasive prenatal testing (NIPT). Although fetal cfDNA is known to be hypomethylated relative to maternal cfDNA, the methylation profile of circulating cfDNA in maternal plasma has not been well studied. We sought to determine whether hypomethylated cfDNA in maternal plasma: (i) could serve as a proxy for fetal fraction and (ii) was reduced in maternal obesity, as the fetal fraction of circulating cfDNA is known to be decreased in the setting of maternal obesity. STUDY DESIGN: In this prospective pilot study, maternal plasma was collected at admission and 24-48h postpartum (PP) from women admitted for delivery at term. Subjects were enrolled into 4 groups: lean (pre-pregnancy BMI <25 kg/m 2 ) no labor (Lean-NL) (n¼15); lean labor (Lean-L) (n¼18); obese (pre-pregnancy BMI !30 kg/m 2 ) no labor (OB-NL) (n¼16); and obese labor (OB-L) (n¼11). Total cfDNA was isolated and genome-wide methylation levels determined using 0.2x coverage whole-genome bisulfite sequencing (WGBS) in all 60 antepartum (AP) samples and in matching PP samples in w5 patients per study group. Calibration was performed using serial dilutions of fully methylated and unmethylated DNA. RESULTS: Hypomethylated cfDNA fraction was significantly lower in OB vs lean pregnant women (27.0 AE0.5% vs 28.5AE0.3%, p¼0.008). Hypomethylated fraction was significantly higher in AP vs PP samples overall, and when stratified by BMI (Fig 1A/B) , demonstrating that the placenta contributes to hypomethylated cfDNA in maternal circulation. However, matched analyses of
